...
GET IN TOUCH

Recognitions

Top 100 Companies to Work For

Aragen was recognised among the “Top 100 Companies to Work For” in Fiscal 2026

July 2026
LinkedIn’s top companies 2026

Aragen Named in LinkedIn’s Top Companies 2026

June 2026
USFDA EIR for Nacharam Unit 1

Aragen receives USFDA EIR for Nacharam unit 1

May 2026

Testimonials

View all Testimonials
Dr Jamie Oliver Chief Medical Officer
STARTON THERAPEUTICS
“We are thoroughly impressed with your level of detail and communication efforts. We thank you and the Aragen team for getting us to this point in the study with confidence that you doing the very best to achieve a successful study.” “We have never had communication from a preclinical group at this level in our combined history of drug product development.”
Stephan Peters, PhD CEO
Mithridate Therapeutics
“I’m working with the Aragen team now for more than twelve years. In every case and study, the team provides a high level of knowledge and service. Helping you to design the right study for you by performing extensive literature searches and exploring experimental possibilities to modify and accommodate models to your needs. Aragen distinguishes itself by service, speed, accuracy, and good communication with customers at a reasonable price”.
Dr. Kathleen Shelton Vice President and Chief Technology Officer
FMC Corporation
“Aragen has been a valued collaborator of FMC for several years. This partnership extends across multiple disciplines in research and development and we appreciate our strong working relationship.”

Publications

View all Publications
2019

Chemistry

Galeterone and the Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-resistant Prostate Cancer Preclinical Models in vitro and in vivo

Andrew K. Kwegyir-Afful, Senthilmurugan Ramalingam, Vidya P. Ramamurthy, Puranik Purushottamachar, Francis N. Murigi, Tadas S. Vasaitis, Weiliang Huang, Maureen A. Kane, Yuji Zhang, Nicholas Ambulos, Sudhir Tiwari, Pratima Srivastava, Ivo P. Nnane, Arif Hussain, Yun Qiu, David J. Weber, Vincent C. O. Njar
(Basel). 2019 Nov; 11(11), 1637

Chemistry

Oxidative Degradation Profile Studies of Tavaborole by a Validated Stability Indicating RP-UPLC method: Isolation and Characterization of Novel Degradant using 2D-NMR and HRMS

Umamaheshwar Puppala , Vishnu Murthy Marisetti, Koduri S V Srinivas, K Venkateshwara Reddy, Muralidharan Kaliyaperumal, Raju Doddipalla
Biomedical Chromatography | Language: English, Database: CAplus and MEDLINE

Biology

Mass Spectrometry as a Workhorse for Preclinical Drug Discovery: Special Emphasis on Drug Metabolism and Pharmacokinetics

Vijayabhaskar Veeravalli, Lakshmi Mohan Vamsi Madgula, Pratima Srivastava
10.5772/intechopen.88385. In book: Mass Spectrometry – Future Perceptions and Applications

Seraphinite AcceleratorOptimized by Seraphinite Accelerator
Turns on site high speed to be attractive for people and search engines.